微创穿刺联合口服阿托伐他汀治疗慢性硬膜下血肿的临床观察
|
摘要
目的探讨慢性硬膜下血肿应用口服阿托伐他汀与微创穿刺联合的治疗方式具有的临床治疗效果,并对患者的预后和出现复发的情况进行分析。方法将80例于2015年11月至2018年10月期间确诊为慢性硬膜下血肿的患者随机平均划分为实验组与对照组。对照组应用钻孔引流术,实验组则应用口服阿托伐他汀联合微创穿刺分别进行治疗。对两组患者的临床疗效、预后以及复发概况进行记录与对比分析。结果治疗后实验组治疗有效率达97. 5%,对照组为75. 0%,P<0. 05,差异具有统计学意义。在手术与症状消失和住院时间方面,实验组均显著低于对照组(P <0. 05)。而在治疗后ADL评分方面,实验组则高于对照组(P <0. 05)。此外,实验组未见复发患者,并发症发生率为5. 0%,而对照组分别为9例(22. 5%)与25. 0%。对上述数据进行统计学分析发现,P <0. 05,差异具有统计学意义。结论利用微创穿刺与阿托伐他汀联合治疗的方式对慢性硬膜下血肿患者进行治疗,临床疗效好,并发症与复发概率低,临床应用价值较好。
Objective To investigate the clinical effect of the combination of artovastatin and minimally invasive puncture on chronic subdural hematoma,and analyze the prognosis and recurrence of the patients. Methods 80 patients diagnosed with chronic subdural hematoma from November 2015 to October 2018 were randomly divided into experimental group and control group on average.Patients in the control group were treated with borehole drainage,while those in the experimental group were treated with atorvastatin combined with minimally invasive puncture. Clinical efficacy,prognosis and recurrence of the two groups were recorded and compared. Results The clinical total effective rate of the experimental group was 97. 5 % and 75. 0 % of the control group,with statistically significant difference(P<0. 05). In term of the duration of surgical and symptom disappearance and length of hospitalization,the experimental group was significantly lower than the control group( P incidence of complications was 5. 0 %,compared with 9 cases(22. 5 %) and 25. 0 % in the control group. According to the statistical analysis above,the difference was statistically significant( P<0. 05). Conclusion The treatment of chronic subdural hematoma by the combination of minimally invasive puncture and atorvastatin has good clinical efficacy,low incidence of complications and recurrence,with great clinical application value.
Objective To investigate the clinical effect of the combination of artovastatin and minimally invasive puncture on chronic subdural hematoma,and analyze the prognosis and recurrence of the patients. Methods 80 patients diagnosed with chronic subdural hematoma from November 2015 to October 2018 were randomly divided into experimental group and control group on average.Patients in the control group were treated with borehole drainage,while those in the experimental group were treated with atorvastatin combined with minimally invasive puncture. Clinical efficacy,prognosis and recurrence of the two groups were recorded and compared. Results The clinical total effective rate of the experimental group was 97. 5 % and 75. 0 % of the control group,with statistically significant difference(P<0. 05). In term of the duration of surgical and symptom disappearance and length of hospitalization,the experimental group was significantly lower than the control group( P incidence of complications was 5. 0 %,compared with 9 cases(22. 5 %) and 25. 0 % in the control group. According to the statistical analysis above,the difference was statistically significant( P<0. 05). Conclusion The treatment of chronic subdural hematoma by the combination of minimally invasive puncture and atorvastatin has good clinical efficacy,low incidence of complications and recurrence,with great clinical application value.
引文
[1]肖爵贤,沈亚徐,余建荣,等. 2种改良术式治疗慢性硬膜下血肿的临床疗效分析[J].中华神经医学杂志,2017,16(6):611-615.
[2]姚文益,殷玉华.慢性硬膜下血肿预后相关因素及双侧出血的危险因素分析[J].上海交通大学学报(医学版),2018,38(4):435-438.
[3]侯梅英,张蕾,程刚,等.慢性硬膜下血肿患者影像学表现及疗效分析[J].河北医药,2018,40(19):2950-2953.
[4]赵印生,衣服新,鲍龙,等.慢性硬膜下血肿钻孔引流术术中冲洗、不冲洗的临床疗效比较[J].锦州医科大学学报,2017,38(3):18-20.
[5]周宇,陈淳,邓发斌,等.不同剂量阿托伐他汀对慢性硬膜下血肿的疗效及安全性评价[J].中国药房,2017,28(5):663-666,667.
[6]谢乐,刘锦平.慢性硬膜下血肿经微创穿刺+阿托伐他汀口服治疗的效果、预后及复发[J].辽宁医学杂志,2016,30(6):28-31.
[7]谈锦科.微创穿刺联合口服阿托伐他汀治疗慢性硬膜下血肿的疗效[J].现代诊断与治疗,2016,27(19):3653-3654.
[8]刘涛,法焕卿.微创穿刺治疗高龄老年人慢性硬膜下血肿的临床观察[J].北京医学,2016,38(1):54-56.
[2]姚文益,殷玉华.慢性硬膜下血肿预后相关因素及双侧出血的危险因素分析[J].上海交通大学学报(医学版),2018,38(4):435-438.
[3]侯梅英,张蕾,程刚,等.慢性硬膜下血肿患者影像学表现及疗效分析[J].河北医药,2018,40(19):2950-2953.
[4]赵印生,衣服新,鲍龙,等.慢性硬膜下血肿钻孔引流术术中冲洗、不冲洗的临床疗效比较[J].锦州医科大学学报,2017,38(3):18-20.
[5]周宇,陈淳,邓发斌,等.不同剂量阿托伐他汀对慢性硬膜下血肿的疗效及安全性评价[J].中国药房,2017,28(5):663-666,667.
[6]谢乐,刘锦平.慢性硬膜下血肿经微创穿刺+阿托伐他汀口服治疗的效果、预后及复发[J].辽宁医学杂志,2016,30(6):28-31.
[7]谈锦科.微创穿刺联合口服阿托伐他汀治疗慢性硬膜下血肿的疗效[J].现代诊断与治疗,2016,27(19):3653-3654.
[8]刘涛,法焕卿.微创穿刺治疗高龄老年人慢性硬膜下血肿的临床观察[J].北京医学,2016,38(1):54-56.